Dr. Crawford has over thirty years’ experience in biotechnology. She joined List Labs in 1989 and served as President from 1999 to 2020. She has an extensive background in bacterial fermentation of aerobes and anaerobes, toxin production, and purification. Dr. Crawford led the List Labs team to build and commission a cGMP parenteral toxin drug manufacturing facility where she supervised cGMP production and upstream processing of a clostridial toxin. During her appointment as President of List Labs., Dr. Crawford managed projects providing quality-controlled anthrax and botulinum toxins to a resource repository. In addition, she directed the development of numerous products including Clostridium difficile and Bacillus anthracis toxins and both the Corynebacterium diphtheriae toxin and the CRM mutant. Dr. Crawford earned her BA in Biochemistry from the University of California, Berkeley, and her PhD in Molecular Biology from Rensselaer Polytechnic Institute. As of June 1, 2020, she becomes the Board Chair of the Company and Board of Directors.